Advanz Pharma (OTCMKTS:CXRXF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Several other analysts have also weighed in on CXRXF. Bloom Burton reissued a “hold” rating on shares of Advanz Pharma in a report on Friday, March 15th. ValuEngine raised Advanz Pharma from a “sell” rating to a “hold” rating in a report on Friday, March 1st.

CXRXF traded down $0.11 during midday trading on Tuesday, reaching $16.99. The company’s stock had a trading volume of 839 shares, compared to its average volume of 1,855. The firm has a market capitalization of $831.07 million, a P/E ratio of 1.44 and a beta of 0.32. The company has a quick ratio of 1.79, a current ratio of 2.10 and a debt-to-equity ratio of 4.50. Advanz Pharma has a twelve month low of $14.40 and a twelve month high of $68.40.

Advanz Pharma Company Profile

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Featured Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.